''It is the wrong time to sell, but we're going to sell anyway,'' he said, betting prices will not recover in the next couple of years. ''We think we'll get 30 to 35% less now than we would have a year ago.''full article here
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
